That's according to Oxford University researchers Peter Horby and Martin Landray, who are conducting treatment experiments as part of the large Recovery Trial – a large, randomised controlled trial of possible treatments for patients admitted to hospital with COVID-19.
Recovery is backed by a grant coordinated by the UK Research and Innovation/National Institute for Health Research (NIHR).
The UK Government's Chief Scientific Adviser, Sir Patrick Vallance, said in Recovery's just-released statement: "This is tremendous news today from the Recovery trial showing that dexamethasone is the first drug to reduce mortality from COVID-19.
NOTE: Core funding to the NIHR for the Recovery Trials is contributed by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, and NIHR Clinical Trials Unit Support Funding.
RELATED: Ebola, Hydroxychloroquine, COVID-19 – WHO Tackles a World of Health Challenges
